8-K: Henry Schein Appoints New CEO, Stanley Bergman to Chair

Henry Schein, Inc. announced the appointment of Frederick M. Lowery as its new Chief Executive Officer, effective March 2, 2026, with current CEO Stanley M. Bergman transitioning to Chairman of the Board.

Summary

• Henry Schein, Inc. has appointed Frederick M. Lowery as its new Chief Executive Officer, effective March 2, 2026.
• Mr. Lowery, 54, previously served as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher Scientific Inc.
• Current CEO, Stanley M. Bergman, will transition to Chairman of the Board upon Mr. Lowery's commencement of employment.
• The Board of Directors expanded from 14 to 15 members, with Mr. Lowery appointed to fill the new vacancy.
• Mr. Lowery's employment agreement includes an annual base salary of $1,250,000 and a target annual bonus opportunity of no less than 150% of base salary.
• For fiscal year 2026, Mr. Lowery's annual bonus payout will be no less than $1,875,000, based on 70% EPS and 30% strategic scorecard results.
• He will receive annual equity awards with an aggregate target grant date fair value of $10,000,000 for fiscal year 2026, allocated as 50% stock options, 25% time-based RSUs, and 25% performance-based RSUs.
• A one-time bonus of $1,184,000 will be paid, contingent on not receiving an annual bonus in 2026 and continued employment.
• A special one-time equity award (Sign-On Award) of $2,500,000 in time-based restricted stock units will be granted, vesting ratably over three years.
• The company will reimburse Mr. Lowery for relocation expenses up to $500,000.
• The Amended and Restated Executive Severance Plan, effective March 2, 2026, now includes the Chief Executive Officer as eligible for Non-CIC Severance Benefits.
• Amendments to the company's By-Laws, effective January 10, 2026, eliminate the requirement for the Board to appoint a President and permit the Board to appoint a CEO who is not also President or Chairman.

Sentiment

Score: 7

Explanation: The filing announces a planned and structured CEO succession, bringing in an experienced industry leader while retaining the former CEO as Chairman for continuity. This is generally a positive sign for stability and future strategic direction, though the significant compensation package and severance terms represent a financial commitment.

Positives

• Frederick M. Lowery brings over two decades of healthcare distribution experience and a strong track record of scaling complex businesses, aligning well with Henry Schein's strategic plan.
• The transition ensures continuity with Stanley M. Bergman remaining as Chairman of the Board, providing experienced leadership during the change.
• Lowery's background in manufacturing, R&D, marketing, and sales functions is expected to accelerate growth and value creation, supporting the BOLD+1 strategic plan.
• The appointment is a result of a comprehensive search process, indicating a deliberate and well-considered succession plan.

Negatives

• The new CEO's compensation package, including a high base salary, significant target bonus, and substantial equity awards, represents a considerable financial commitment for the company.
• The severance provisions for the CEO, including 2x base salary plus average annual bonus for non-CIC termination and 2.5x base salary plus target bonus for CIC termination, are generous and could result in significant payouts.

Risks

• Dependence on third parties for product manufacture, supply, and raw materials.
• Risks related to achieving strategic growth objectives, including restructuring and value creation initiatives.
• Challenges associated with senior company leadership transitions, including potential disruption.
• Ability to develop, acquire, maintain, and protect new products and services, and utilize new technologies that achieve market acceptance with acceptable margins.
• Transitional challenges with acquisitions and joint ventures, including failure to achieve anticipated synergies/benefits and demands on operational, information systems, legal, regulatory, compliance, financial, and human resources functions.
• Certain provisions in governing documents that may discourage third-party acquisitions.
• Adverse changes in supplier rebates or other purchasing incentives.
• Security risks associated with information systems and technology products and services, such as cyberattacks or data security breaches (e.g., October 2023 incident).
• Effects of a highly competitive and consolidating market, including competition from third-party online commerce sites.
• Political, economic, and regulatory influences on the healthcare industry.
• General global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment, consumer confidence, sovereign debt levels, and currency fluctuations.
• Failure to comply with existing and future regulatory requirements, including those related to healthcare and the EU Medical Device Regulation.
• Changes in tax legislation, tax rates, and availability of certain tax deductions.
• Risks related to product liability, intellectual property, and other claims.
• Risks associated with customs policies or legislative import restrictions.
• Risks associated with disease outbreaks, epidemics, pandemics (e.g., COVID-19), or similar public health concerns and other natural or man-made disasters.
• Risks associated with global operations and geopolitical conflicts (e.g., war in Ukraine, Israel-Gaza war).
• Changes to laws and policies governing foreign trade, tariffs, and sanctions.
• Supply chain disruption.
• Litigation risks and new or unanticipated litigation developments.
• Dependence on senior management, employee hiring and retention, increases in labor or healthcare costs, and relationships with customers, suppliers, and manufacturers.
• Disruptions in financial markets.

Future Outlook

The company anticipates that Frederick M. Lowery's extensive experience in healthcare distribution and operational excellence will guide Henry Schein into its next phase of growth and continued execution of its BOLD+1 strategic plan. The transition of Stanley M. Bergman to Chairman is intended to ensure a smooth and effective leadership change, supporting future strategic initiatives.

Management Comments

• Frederick M. Lowery: "I am honored to join Henry Schein at such a pivotal moment. This is an organization with immense potential to impact clinicians and patients, given its remarkable reputation for innovation, customer service, and partnership. I look forward to working with Team Schein to build on the strong foundation established by Stan while accelerating value creation."
• Stanley M. Bergman: "I am very pleased to welcome Fred to Henry Schein. Beyond his extensive operational experience, he brings a leadership philosophy that reflects the values that have long defined our Company. Fred understands the critical role we play in supporting dental and medical practitioners, and he is exceptionally well equipped to lead Henry Schein into its next phase of growth."
• Phil Laskawy (Lead Director and Chair of the Nominating and Governance Committee): "After a comprehensive search process, we are confident that Fred is the right successor to honor Henry Schein’s proud heritage. With extensive commercial, logistics, and manufacturing expertise, and a focus on customer satisfaction, he has the combination of experience and capabilities necessary to accelerate growth and value creation."
• Max Lin (Board Member and Vice Chair of the Nominating and Governance Committee at Henry Schein and Partner at KKR): "We believe Fred brings a unique combination of healthcare distribution experience, operational best practices, and accountable leadership that will accelerate our strategic initiatives and further differentiate Henry Schein as a world-class business."

Industry Context

This executive leadership transition at Henry Schein reflects a common practice in mature companies to ensure long-term strategic continuity and fresh perspectives. The appointment of an industry veteran from a major competitor like Thermo Fisher Scientific highlights the competitive landscape for top talent in the healthcare distribution sector. The focus on 'scaling complex businesses' and 'operational excellence' suggests an industry trend towards optimizing supply chains and leveraging technology for efficiency and growth, especially in the context of evolving healthcare delivery models and increasing digital integration.

Comparison to Industry Standards

• The appointment of an external candidate with extensive experience from a large, diversified scientific and healthcare company like Thermo Fisher Scientific (NYSE: TMO) is a common strategy for companies seeking to inject new perspectives and accelerate growth, similar to leadership changes seen at other major healthcare distributors or medical device companies.
• The compensation package for the new CEO, including a base salary of $1.25 million, a target bonus of 150% of base, and $10 million in annual equity awards, is competitive for a CEO of a Fortune 500 company in the healthcare distribution sector, aligning with packages observed at peers such as McKesson Corporation (NYSE: MCK) or Cardinal Health (NYSE: CAH) for similar roles, though specific direct comparisons would require detailed peer group analysis.
• The severance provisions, offering 2x base plus average bonus for non-CIC termination and 2.5x base plus target bonus for CIC termination, are within the typical range for CEO employment agreements at large public companies, designed to attract and retain top executive talent by providing financial security in the event of an involuntary separation or change of control.
• The transition of the outgoing CEO, Stanley M. Bergman, to Chairman of the Board is a well-established corporate governance practice, often employed to facilitate a smooth leadership handover, retain institutional knowledge, and maintain strategic oversight during a period of change, a model seen in various industries.

Management Changes

Corporate Governance

Related Party Transactions

• No arrangement or understanding exists between Mr. Lowery and any other person pursuant to which Mr. Lowery was selected to serve as Chief Executive Officer.
• There have been no related party transactions between the Company or any of its subsidiaries and Mr. Lowery reportable under Item 404(a) of Regulation S-K.
• Mr. Lowery has no family relationships with any of the Company's directors or executive officers.

Stakeholder Impact

• Shareholders: Potential for enhanced strategic execution and value creation under new leadership, balanced against significant executive compensation and severance commitments. The continuity with Bergman as Chairman may reassure investors.
• Employees: A new CEO may bring changes in corporate culture, strategic priorities, and operational approaches. The retention of Bergman as Chairman could provide stability.
• Customers: Lowery's experience in healthcare distribution and customer channels suggests a continued focus on customer satisfaction and service, potentially leading to improved offerings.
• Suppliers/Creditors: No immediate direct impact indicated, but strategic shifts under new leadership could influence future business relationships or financial stability.

Next Steps

• Frederick M. Lowery will commence employment as Chief Executive Officer and join the Board of Directors on March 2, 2026.
• Stanley M. Bergman will continue as Chief Executive Officer until March 2, 2026, then transition to Chairman of the Board.
• Mr. Lowery will be eligible to receive annual equity awards in fiscal year 2026, subject to Compensation Committee approval and performance criteria.

Key Dates

Recommendation

The appointment of a new CEO is a significant event, but this appears to be a well-managed succession plan with the outgoing CEO remaining as Chairman, suggesting stability. Frederick Lowery's extensive industry experience is a positive, aligning with the company's strategic goals. However, the substantial compensation package and severance terms, while competitive, represent a considerable financial commitment. Given the planned nature of the transition and the retention of key leadership, a 'hold' recommendation is appropriate as the market digests the implications of the new leadership and awaits initial performance under Mr. Lowery's direction. There are no immediate red flags or overwhelmingly positive catalysts to warrant a 'buy' or 'sell' at this juncture.

Keywords

CEO appointment, executive leadership change, corporate governance, succession plan, healthcare solutions, dental, medical, SEC filing, 8-K, Henry Schein, HSIC, Frederick Lowery, Stanley Bergman, Thermo Fisher Scientific, executive compensation, severance plan, bylaws amendment, stock options, restricted stock units, strategic plan